BioSpace News Archive

Inari, a company that is advancing plant breeding by tapping nature’s genetic diversity, continues to expand its capabilities with exclusive patent licenses to technologies developed at Cold Spring Harbor Laboratory (CSHL).

Antibe Therapeutics Inc. highlights that a research article has been published in the British Journal of Pharmacology on the successful Phase 2B GI safety trial for its lead drug, ATB-346.

KSQ Therapeutics announced the appointment of Douglas Pagán as Chief Financial Officer.

Lisa Shafer, Ph.D., Chief Scientific Officer, and Eric Distad, Vice President of Clinical Development, add Extensive CNS Drug-Device Development Experience

Thermo Fisher and NX Prenatal to develop clinical mass spectrometry-based workflows for monitoring maternal and fetal health during pregnancy and evaluating risk of complications

Aurora Cannabis Inc. (“Aurora”) (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and Hempco Food and Fiber Inc. (“Hempco”) (TSX-V: HEMP) today announced that the companies have entered into a binding letter agreement (the “Letter Agreement”) in regard to the basic terms and conditions upon which Aurora will acquire all of the issued and outstanding common shares of Hempco

Ensysce is developing proprietary TAAPTM/MPARTM prodrug delivery and overdose technology to stem the opioid abuse epidemic

Tecnoplanta Expands its Portfolio with MyoPro®

Vault CDMS provides a suite of clinical data management applications that combines coding, EDC, data cleaning, and reporting all on a single cloud platform.

Reimbursement of the device marks a key milestone in the Company’s relationship with major U.S. private insurers.